Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer
Advanced Science · 2026
DOI: 10.1002/advs.76895 ↗At a glance
Journal article in Advanced Science, 2026. Written by Ping Xu and 9 co-authors. Institution: Institute of Hepatobiliary-Pancreatic-Intestinal Diseases, Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanch…. Major MEDLINE topics: Oxaliplatin, Colorectal Neoplasms, Drug Resistance, Neoplasm, Antineoplastic Agents. 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Sichuan, Natural Science Foundation of North Sichuan Medical College.
Abstract (original language)
Although a small subset of colorectal cancer (CRC) patients benefit from immunotherapy, oxaliplatin (OXA)‐based chemotherapy remains the first‐line treatment. However, the widespread development of OXA resistance poses a major clinical challenge, and the underlying molecular mechanisms remain incompletely understood. In this study, we found that Tex10 deficiency markedly enhances OXA sensitivity in CRC cells by inducing cytostatic autophagy in xenograft and patient‐derived organoid models. Tex10 −/− mice exhibit markedly reduced tumor numbers and decreased p62 levels in inflammation‐induced CRC. Mechanistically, we determined that Tex10 competitively binds BRD9, thereby disrupting the BRD9‐BRG1 interaction within the non‐canonical BAF (ncBAF) complex, which suppresses AMBRA1 transcription and ULK1 ubiquitination to inhibit autophagy. Furthermore, in silico screening identified gemcitabine (GEM) as a potent Tex10 inhibitor. GEM directly binds to the N268 residue of Tex10, reducing Tex10 abundance and unleashing autophagy. This, in turn facilitates further lysosomal degradation of Tex10, forming a potent positive‐feedback loop to overcome OXA resistance. In addition, Tex10 deletion enhances the antitumor efficacy of immunotherapy by inhibiting lysosomal degradation of PD‐L1. Collectively, this study uncovers a previously unrecognized antitumor mechanism of GEM and identifies Tex10 as a promising therapeutic target for overcoming OXA resistance and potentiating immunotherapy in CRC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Hepatobiliary-Pancreatic-Intestinal Diseases, Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, China.
- Sichuan Clinical Research Center for Digestive Diseases, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Hepatobiliary Surgery, The Fourth People's Hospital of Zigong, Zigong, China.
- Institute of Materia Medica, School of Pharmacy, North Sichuan Medical College, Nanchong, China.
- Institute of Basic Medicine, School of Basic Medical Sciences and Forensic Medicine, North Sichuan Medical College, Nanchong, China.
ORCID profiles: Jie Huang, Lin Deng, Chunlei Yu, Xiaocong Xiang
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan
- Natural Science Foundation of North Sichuan Medical College
- Research and Development Project of Affiliated Hospital of North Sichuan Medical College
Cite
APA
Xu, P., Huang, J., Gao, X., Deng, L., Deng, Y., Wang, D., Yu, C., Zhang, Y., Li, J., & Xiang, X. (2026). Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer. Advanced Science. https://doi.org/10.1002/advs.76895
Vancouver
Xu P, Huang J, Gao X, Deng L, Deng Y, Wang D, et al. Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer. Advanced Science. 2026. doi:10.1002/advs.76895
BibTeX
@article{Xu2026,
author = {Xu, Ping and Huang, Jie and Gao, Xiaojin and Deng, Lin and Deng, Yanheng and Wang, Denglu and Yu, Chunlei and Zhang, Yunxiang and Li, Jingdong and Xiang, Xiaocong},
title = {Targeting Tex10 Overcomes Oxaliplatin Resistance by Competitively Disrupting the Non‐Canonical BAF Complex in Colorectal Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76895}
}
EUVIMED